{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T17:29:39Z","timestamp":1790357379707,"version":"4.1.0"},"reference-count":125,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,5,9]],"date-time":"2019-05-09T00:00:00Z","timestamp":1557360000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003819","name":"Natural Science Foundation of Hubei Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003819","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2019.01050","type":"journal-article","created":{"date-parts":[[2019,5,9]],"date-time":"2019-05-09T10:17:08Z","timestamp":1557397028000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":45,"title":["DPP-4 Inhibitors as Potential Candidates for Antihypertensive Therapy: Improving Vascular Inflammation and Assisting the Action of Traditional Antihypertensive Drugs"],"prefix":"10.3389","volume":"10","author":[{"given":"Jianqiang","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuyue","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jixin","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaohong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quan","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2019,5,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.ijcard.2015.06.076","article-title":"Dpp4 inhibition as a therapeutic strategy in cardiometabolic disease: Incretin-dependent and -independent function","volume":"197","author":"Gong","year":"2015","journal-title":"Int J Cardiol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1161\/HYPERTENSIONAHA.116.07797","article-title":"Angiotensin-converting enzyme inhibitor use and major cardiovascular outcomes in type 2 diabetes mellitus treated with the dipeptidyl peptidase 4 inhibitor alogliptin","volume":"68","author":"White","year":"2016","journal-title":"Hypertension."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","article-title":"Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus","volume":"369","author":"Scirica","year":"2013","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1177\/1479164116629352","article-title":"Effects of dipeptidyl peptidase-4 inhibitors on cardiac and endothelial function in type 2 diabetes mellitus: a pilot study","volume":"13","author":"Leung","year":"2016","journal-title":"Diab Vasc Dis Res."},{"key":"B5","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1016\/j.ijcard.2016.08.306","article-title":"Inhibition of DPP-4 by alogliptin improves coronary flow reserve and left ventricular systolic function evaluated by phase contrast cine magnetic resonance imaging in patients with type 2 diabetes and coronary artery disease","volume":"223","author":"Kato","year":"2016","journal-title":"Int J Cardiol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1161\/CIRCIMAGING.109.899377","article-title":"DPP-4 inhibition by sitagliptin improves the myocardial response to dobutamine stress and mitigates stunning in a pilot study of patients with coronary artery disease","volume":"3","author":"Read","year":"2010","journal-title":"Circ Cardiovasc Imaging"},{"key":"B7","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s12933-016-0493-3","article-title":"A randomised, active- and placebo-controlled, three-period crossover trial to investigate short-term effects of the dipeptidyl peptidase-4 inhibitor linagliptin on macro- and microvascular endothelial function in type 2 diabetes","volume":"16","author":"Jax","year":"2017","journal-title":"Cardiovasc Diabetol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/s12933-016-0468-4","article-title":"Effect of trelagliptin on vascular endothelial functions and serum adiponectin level in patients with type 2 diabetes: a preliminary single-arm prospective pilot study","volume":"15","author":"Ida","year":"2016","journal-title":"Cardiovasc Diabetol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1620\/tjem.223.133","article-title":"Sitagliptin, a dipeptidyl peptidase-4 inhibitor, decreases systolic blood pressure in Japanese hypertensive patients with type 2 diabetes","volume":"223","author":"Ogawa","year":"2011","journal-title":"Tohoku J Exp Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s13098-016-0144-6","article-title":"Dipeptidyl peptidase-4 inhibitors improve arterial stiffness, blood pressure, lipid profile and inflammation parameters in patients with type 2 diabetes mellitus","volume":"8","author":"Duvnjak","year":"2016","journal-title":"Diabetol Metab Syndr."},{"key":"B11","doi-asserted-by":"publisher","first-page":"337","DOI":"10.2147\/VHRM.S112148","article-title":"Blood pressure and fasting lipid changes after 24 weeks' treatment with vildagliptin: a pooled analysis in >2,000 previously drug-naive patients with type 2 diabetes mellitus","volume":"12","author":"Evans","year":"2016","journal-title":"Vasc Health Risk Manag."},{"key":"B12","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1089\/met.2018.0010","article-title":"Saxagliptin upregulates nesfatin-1 secretion and ameliorates insulin resistance and metabolic profiles in type 2 diabetes mellitus","volume":"16","author":"Chen","year":"2018","journal-title":"Metab Syndr Relat Disord"},{"key":"B13","first-page":"2385","article-title":"Beneficial effects of sitagliptin and metformin in non-diabetic hypertensive and dyslipidemic patients","volume":"29","author":"Hussain","year":"2016","journal-title":"Pak J Pharm Sci."},{"key":"B14","doi-asserted-by":"publisher","first-page":"188","DOI":"10.14740\/jocmr2820w","article-title":"Primary care-based investigation of the effect of sitagliptin on blood pressure in hypertensive patients with type 2 diabetes","volume":"9","author":"Yuasa","year":"2017","journal-title":"J Clin Med Res."},{"key":"B15","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1097\/HJH.0b013e328341939d","article-title":"Dipeptidyl peptidase IV inhibition attenuates blood pressure rising in young spontaneously hypertensive rats","volume":"29","author":"Pacheco","year":"2011","journal-title":"J Hypertens."},{"key":"B16","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1161\/HYPERTENSIONAHA.112.195115","article-title":"Dipeptidyl peptidase 4 inhibitor sitagliptin protects endothelial function in hypertension through a glucagon-like peptide 1-dependent mechanism","volume":"60","author":"Liu","year":"2012","journal-title":"Hypertension."},{"key":"B17","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/hr.2014.173","article-title":"Effect of dipeptidyl peptidase-4 inhibition on circadian blood pressure during the development of salt-dependent hypertension in rats","volume":"38","author":"Sufiun","year":"2015","journal-title":"Hypertens Res."},{"key":"B18","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1097\/FJC.0b013e31826be204","article-title":"Dipeptidyl peptidase-4 inhibition with saxagliptin enhanced nitric oxide release and reduced blood pressure and sICAM-1 levels in hypertensive rats","volume":"60","author":"Mason","year":"2012","journal-title":"J Cardiovasc Pharmacol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1097\/GME.0000000000000640","article-title":"Estrogen and DPP4 inhibitor, but not metformin, exert cardioprotection via attenuating cardiac mitochondrial dysfunction in obese insulin-resistant and estrogen-deprived female rats","volume":"23","author":"Sivasinprasasn","year":"2016","journal-title":"Menopause."},{"key":"B20","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1159\/000341487","article-title":"DPP-4 inhibition on top of angiotensin receptor blockade offers a new therapeutic approach for diabetic nephropathy","volume":"36","author":"Alter","year":"2012","journal-title":"Kidney Blood Press Res."},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0b013e3283649b4d","article-title":"Effects of telmisartan and linagliptin when used in combination on blood pressure and oxidative stress in rats with 2-kidney-1-clip hypertension","author":"Chaykovska","year":"2013","journal-title":"J Hypertens."},{"key":"B22","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1161\/HYPERTENSIONAHA.110.156554","article-title":"Interactive hemodynamic effects of dipeptidyl peptidase-IV inhibition and angiotensin-converting enzyme inhibition in humans","volume":"56","author":"Marney","year":"2010","journal-title":"Hypertension"},{"key":"B23","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1161\/HYPERTENSIONAHA.114.04631","article-title":"Effect of dipeptidyl peptidase 4 inhibition on arterial blood pressure is context dependent","volume":"65","author":"Jackson","year":"2015","journal-title":"Hypertension"},{"key":"B24","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1016\/S0140-6736(12)61766-8","article-title":"A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990\u20132010: a systematic analysis for the global burden of disease study 2010","volume":"380","author":"Lim","year":"2012","journal-title":"Lancet."},{"key":"B25","doi-asserted-by":"publisher","first-page":"37","DOI":"10.2147\/IBPC.S150628","article-title":"Blood pressure control status and associated factors among adult hypertensive patients on outpatient follow-up at University of Gondar Referral Hospital, northwest Ethiopia: a retrospective follow-up study","volume":"11","author":"Animut","year":"2018","journal-title":"Integr Blood Press Contr."},{"key":"B26","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.cjca.2012.06.009","article-title":"The immune system: role in hypertension","volume":"29","author":"Schiffrin","year":"2013","journal-title":"Can J Cardiol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s11906-011-0224-9","article-title":"Immune mechanisms in hypertension","volume":"13","author":"Leibowitz","year":"2011","journal-title":"Curr Hypertens Rep"},{"key":"B28","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1097\/00041552-200303000-00009","article-title":"Vascular inflammation: a role in vascular disease in hypertension?","volume":"12","author":"Virdis","year":"2003","journal-title":"Curr Opin Nephrol Hypertens."},{"key":"B29","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.mvr.2018.07.005","article-title":"Constitutive DPP4 activity, inflammation, and microvascular reactivity in subjects with excess body weight and without diabetes","volume":"120","author":"da Silva J\u00fanior","year":"2018","journal-title":"Microvasc Res."},{"key":"B30","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1161\/HYPERTENSIONAHA.109.145094","article-title":"Interleukin 17 promotes angiotensin II-induced hypertension and vascular dysfunction","volume":"55","author":"Madhur","year":"2010","journal-title":"Hypertension"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1681\/ASN.2006070707","article-title":"Human T and natural killer cells possess a functional renin-angiotensin system: further mechanisms of angiotensin II-induced inflammation","volume":"18","author":"Jurewicz","year":"2007","journal-title":"J Am Soc Nephrol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"R208","DOI":"10.1152\/ajpregu.90521.2008","article-title":"Regulation of T-cell function by endogenously produced angiotensin II","volume":"296","author":"Hoch","year":"2009","journal-title":"Am J Physiol Regul Integr Comp Physiol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1111\/j.1365-3083.1989.tb01108.x","article-title":"Dipeptidyl peptidase IV in human T lymphocytes","volume":"29","author":"Schon","year":"1989","journal-title":"Scand J Immunol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"2266","DOI":"10.1210\/en.2013-1920","article-title":"Prevention of obesity-induced renal injury in male mice by DPP4 inhibition","volume":"155","author":"Nistala","year":"2014","journal-title":"Endocrinology."},{"key":"B35","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1161\/CIRCULATIONAHA.111.041418","article-title":"Long-term dipeptidyl-peptidase 4 inhibition reduces atherosclerosis and inflammation via effects on monocyte recruitment and chemotaxis","volume":"124","author":"Shah","year":"2011","journal-title":"Circulation"},{"key":"B36","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.vph.2017.03.003","article-title":"Teneligliptin, a dipeptidyl peptidase-4 inhibitor, attenuated pro-inflammatory phenotype of perivascular adipose tissue and inhibited atherogenesis in normoglycemic apolipoprotein-E-deficient mice","author":"Salim","year":"2017","journal-title":"Vascul Pharmacol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1056\/NEJMra0707449","article-title":"Interleukin-17 and type 17 helper T cells","volume":"361","author":"Miossec","year":"2009","journal-title":"N Engl J Med."},{"key":"B38","doi-asserted-by":"publisher","first-page":"5438","DOI":"10.4049\/jimmunol.1103801","article-title":"Human Th17 cells express high levels of enzymatically active dipeptidylpeptidase IV (CD26)","volume":"188","author":"Bengsch","year":"2012","journal-title":"J Immunol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"3592","DOI":"10.1210\/en.2017-00416","article-title":"Dipeptidyl peptidase-4 inhibition with saxagliptin ameliorates angiotensin II-induced cardiac diastolic dysfunction in male mice","volume":"158","author":"Brown","year":"2017","journal-title":"Endocrinology"},{"key":"B40","doi-asserted-by":"publisher","first-page":"3793","DOI":"10.3892\/etm.2018.6668","article-title":"The relationship between inflammatory factor expression and blood pressure and urinary protein in the placenta of gestational hypertension rats","volume":"16","author":"Jia","year":"2018","journal-title":"Exp Ther Med."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1161\/HYPERTENSIONAHA.109.146902","article-title":"Ribonucleic acid interference knockdown of interleukin 6 attenuates cold-induced hypertension","volume":"55","author":"Crosswhite","year":"2010","journal-title":"Hypertension."},{"key":"B42","doi-asserted-by":"publisher","first-page":"4070","DOI":"10.1111\/bph.13686","article-title":"Sitagliptin reduces inflammation, fibrosis and preserves diastolic function in a rat model of heart failure with preserved ejection fraction","volume":"174","author":"Esposito","year":"2017","journal-title":"Br J Pharmacol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1159\/000490688","article-title":"Anti-inflammatory action of sitagliptin and linagliptin in doxorubicin nephropathy","volume":"43","author":"Jo","year":"2018","journal-title":"Kidney Blood Press Res"},{"key":"B44","doi-asserted-by":"publisher","first-page":"R713","DOI":"10.1152\/ajpregu.00712.2009","article-title":"Interleukin-10 reduces inflammation, endothelial dysfunction, and blood pressure in hypertensive pregnant rats","volume":"298","author":"Tinsley","year":"2010","journal-title":"Am J Physiol Regul Integr Comp Physiol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1161\/CIRCRESAHA.114.301958","article-title":"Cardiovascular actions of incretin-based therapies","volume":"114","author":"Ussher","year":"2014","journal-title":"Circ Res."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1161\/HYPERTENSIONAHA.115.05779","article-title":"Obligatory role for B cells in the development of angiotensin II-dependent hypertension","volume":"66","author":"Chan","year":"2015","journal-title":"Hypertension."},{"key":"B47","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/0008-8749(91)90343-A","article-title":"Expression of the rat CD26 antigen (dipeptidyl peptidase IV) on subpopulations of rat lymphocytes","volume":"134","author":"Gorrell","year":"1991","journal-title":"Cell Immunol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"2076","DOI":"10.2337\/dc12-0199","article-title":"Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes: role of dipeptidyl peptidase-IV inhibition","volume":"35","author":"Rizzo","year":"2012","journal-title":"Diabetes Care."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1210\/en.2012-1855","article-title":"Anagliptin, a DPP-4 inhibitor, suppresses proliferation of vascular smooth muscles and monocyte inflammatory reaction and attenuates atherosclerosis in male apo E-deficient mice","volume":"154","author":"Ervinna","year":"2013","journal-title":"Endocrinology."},{"key":"B50","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.mce.2015.01.025","article-title":"The dipeptidyl peptidase-IV inhibitor inhibits the expression of vascular adhesion molecules and inflammatory cytokines in HUVECs via Akt- and AMPK-dependent mechanisms","volume":"405","author":"Hwang","year":"2015","journal-title":"Mol Cell Endocrinol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"162092","DOI":"10.1155\/2011\/162092","article-title":"Diabetic nephropathy amelioration by a low-dose sitagliptin in an animal model of type 2 diabetes (zucker diabetic fatty rat)","volume":"2011","author":"Mega","year":"2015","journal-title":"Exp. Diabetes Res."},{"key":"B52","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s13098-015-0095-3","article-title":"DPP-4 inhibitor sitagliptin prevents inflammation and oxidative stress of heart and kidney in two kidney and one clip (2K1C) rats","volume":"7","author":"Alam","year":"2015","journal-title":"Diabetol Metab Syndr."},{"key":"B53","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/s12933-014-0157-0","article-title":"DPP-4 inhibitor linagliptin ameliorates cardiovascular injury in salt-sensitive hypertensive rats independently of blood glucose and blood pressure","volume":"13","author":"Koibuchi","year":"2014","journal-title":"Cardiovasc Diabetol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1007\/s11033-012-2290-8","article-title":"GLP-1-dependent and independent effects and molecular mechanisms of a dipeptidyl peptidase 4 inhibitor in vascular endothelial cells","volume":"40","author":"Hu","year":"2013","journal-title":"Mol Biol Rep."},{"key":"B55","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/1475-2840-12-125","article-title":"Advanced glycation end products evoke endothelial cell damage by stimulating soluble dipeptidyl peptidase-4 production and its interaction with mannose 6-phosphate\/insulin-like growth factor II receptor","volume":"12","author":"Ishibashi","year":"2013","journal-title":"Cardiovasc Diabetol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1016\/j.metabol.2011.01.010","article-title":"Glucagon-like peptide-1 suppresses advanced glycation end product-induced monocyte chemoattractant protein-1 expression in mesangial cells by reducing advanced glycation end product receptor level","volume":"60","author":"Ishibashi","year":"2011","journal-title":"Metabolism."},{"key":"B57","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.vph.2015.07.005","article-title":"Dipeptidyl peptidase-4 inhibition by gemigliptin prevents abnormal vascular remodeling via NF-E2-related factor 2 activation","volume":"73","author":"Choi","year":"2015","journal-title":"Vascul Pharmacol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"2256","DOI":"10.1007\/s00125-010-1831-8","article-title":"A glucagon-like peptide-1 (GLP-1) analogue, liraglutide, upregulates nitric oxide production and exerts anti-inflammatory action in endothelial cells","volume":"53","author":"Hattori","year":"2010","journal-title":"Diabetologia."},{"key":"B59","doi-asserted-by":"publisher","first-page":"E214","DOI":"10.1152\/ajpendo.00553.2014","article-title":"DPP-IV inhibitor anagliptin exerts anti-inflammatory effects on macrophages, adipocytes, and mouse livers by suppressing NF-kappaB activation","volume":"309","author":"Shinjo","year":"2015","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"B60","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1093\/eurheartj\/ehr304","article-title":"Nitric oxide synthases: regulation and function","volume":"33","author":"Forstermann","year":"2012","journal-title":"Eur Heart J"},{"key":"B61","doi-asserted-by":"publisher","first-page":"774","DOI":"10.5551\/jat.7666","article-title":"Effect of enhanced glycemic control with saxagliptin on endothelial nitric oxide release and CD40 levels in obese rats","volume":"18","author":"Mason","year":"2011","journal-title":"J Atheroscler Thromb."},{"key":"B62","doi-asserted-by":"publisher","first-page":"27235","DOI":"10.1074\/jbc.M114.557835","article-title":"Vildagliptin stimulates endothelial cell network formation and ischemia-induced revascularization via an endothelial nitric-oxide synthase-dependent mechanism","volume":"289","author":"Ishii","year":"2014","journal-title":"J Biol Chem."},{"key":"B63","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.2174\/09298673113206660273","article-title":"MK-0626, a dipeptidyl peptidase-4 inhibitor, improves neovascularization by increasing both the number of circulating endothelial progenitor cells and endothelial nitric oxide synthetase expression","volume":"21","author":"Shih","year":"2014","journal-title":"Curr Med Chem."},{"key":"B64","doi-asserted-by":"publisher","first-page":"2501","DOI":"10.1210\/en.2013-1096","article-title":"Dipeptidylpeptidase inhibition is associated with improvement in blood pressure and diastolic function in insulin-resistant male Zucker obese rats","volume":"154","author":"Aroor","year":"2013","journal-title":"Endocrinology."},{"key":"B65","doi-asserted-by":"publisher","first-page":"H477","DOI":"10.1152\/ajpheart.00209.2014","article-title":"Pleiotropic effects of the dipeptidylpeptidase-4 inhibitors on the cardiovascular system","volume":"307","author":"Aroor","year":"2014","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"B66","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1093\/ajh\/hpt196","article-title":"Effect of GLP-1 mimetics on blood pressure and relationship to weight loss and glycemia lowering: results of a systematic meta-analysis and meta-regression","volume":"27","author":"Katout","year":"2014","journal-title":"Am J Hypertens."},{"key":"B67","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.regpep.2004.08.024","article-title":"Glucagon-like peptide-1 relaxes rat conduit arteries via an endothelium-independent mechanism","volume":"125","author":"Nystrom","year":"2005","journal-title":"Regul Pept"},{"key":"B68","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1161\/CIRCULATIONAHA.107.739938","article-title":"Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways","volume":"117","author":"Ban","year":"2008","journal-title":"Circulation."},{"key":"B69","doi-asserted-by":"publisher","first-page":"E1289","DOI":"10.1152\/ajpendo.00373.2007","article-title":"Beneficial effects of GLP-1 on endothelial function in humans: dampening by glyburide but not by glimepiride","volume":"293","author":"Basu","year":"2007","journal-title":"Am J Physiol Endocrinol Metab."},{"key":"B70","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1210\/jc.2015-3293","article-title":"Insulin enhances endothelial function throughout the arterial tree in healthy but not metabolic syndrome subjects","volume":"101","author":"Jahn","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"B71","doi-asserted-by":"publisher","first-page":"E355","DOI":"10.1152\/ajpendo.00283.2013","article-title":"GLP-1 increases microvascular recruitment but not glucose uptake in human and rat skeletal muscle","volume":"306","author":"Sjoberg","year":"2014","journal-title":"Am J Physiol Endocrinol Metab."},{"key":"B72","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1111\/dom.12835","article-title":"Exenatide induces an increase in vasodilatory and a decrease in vasoconstrictive mediators","volume":"19","author":"Chaudhuri","year":"2017","journal-title":"Diabetes Obes Metab."},{"key":"B73","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1177\/107424840400900406","article-title":"Vascular effects of natriuretic peptides in healthy men","volume":"9","author":"Komarek","year":"2004","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"B74","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.ejphar.2004.07.008","article-title":"Sympathetic co-transmission: the coordinated action of ATP and noradrenaline and their modulation by neuropeptide Y in human vascular neuroeffector junctions","volume":"500","author":"Pablo","year":"2004","journal-title":"Eur J Pharmacol."},{"key":"B75","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1054\/npep.1999.0017","article-title":"Regulatory peptides in the heart and major vessels of man and mammals","volume":"33","author":"Onuoha","year":"1999","journal-title":"Neuropeptides"},{"key":"B76","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1161\/HYPERTENSIONAHA.108.112532","article-title":"Sitagliptin augments sympathetic enhancement of the renovascular effects of angiotensin II in genetic hypertension","volume":"51","author":"Jackson","year":"2008","journal-title":"Hypertension."},{"key":"B77","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1161\/01.HYP.0000197033.54756.83","article-title":"Pancreatic polypeptide-fold peptide receptors and angiotensin II-induced renal vasoconstriction","volume":"47","author":"Dubinion","year":"2006","journal-title":"Hypertension."},{"key":"B78","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1159\/000159011","article-title":"Neuropeptide Y increases force development through a mechanism that involves calcium entry in resistance arteries","volume":"30","author":"Andriantsitohaina","year":"1993","journal-title":"J Vasc Res"},{"key":"B79","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1007\/BF00168634","article-title":"Effects of noradrenaline and neuropeptide Y on rat mesenteric microvessel contraction","volume":"353","author":"Chen","year":"1996","journal-title":"Naunyn Schmiedebergs Arch Pharmacol."},{"key":"B80","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s002109900175","article-title":"Gender and hypertension interact to regulate neuropeptide Y receptor responsiveness","volume":"361","author":"Bischoff","year":"2000","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"B81","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1038\/sj.bjp.0703256","article-title":"Neuropeptide Y regulates intracellular calcium through different signalling pathways linked to a Y(1)-receptor in rat mesenteric small arteries","volume":"129","author":"Prieto","year":"2000","journal-title":"Br J Pharmacol"},{"key":"B82","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3892\/ijmm.15.1.3","article-title":"Neuropeptide-Y and Y-receptors in the autocrine-paracrine regulation of adrenal gland under physiological and pathophysiological conditions (Review)","volume":"15","author":"Spinazzi","year":"2005","journal-title":"Int J Mol Med."},{"key":"B83","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1210\/jc.2003-031907","article-title":"Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes","volume":"89","author":"Ahren","year":"2004","journal-title":"J Clin Endocrinol Metab."},{"key":"B84","doi-asserted-by":"publisher","first-page":"4643","DOI":"10.1016\/j.ijcard.2013.07.190","article-title":"Substance P acting via the neurokinin-1 receptor regulates adverse myocardial remodeling in a rat model of hypertension","volume":"168","author":"Dehlin","year":"2013","journal-title":"Int J Cardiol."},{"key":"B85","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1161\/HYPERTENSIONAHA.113.02767","article-title":"Substance P increases sympathetic activity during combined angiotensin-converting enzyme and dipeptidyl peptidase-4 inhibition","volume":"63","author":"Devin","year":"2014","journal-title":"Hypertension."},{"key":"B86","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1111\/j.1440-1681.2007.04737.x","article-title":"Effects of dipeptidyl peptidase iv inhibition on arterial blood pressure","volume":"35","author":"Jackson","year":"2008","journal-title":"Clin Exp Pharmacol Physiol."},{"key":"B87","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1210\/er.2011-1052","article-title":"Cardiovascular biology of the incretin system","volume":"33","author":"Ussher","year":"2012","journal-title":"Endocr Rev."},{"key":"B88","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1093\/cvr\/cvq271","article-title":"GLP-1 receptor stimulation depresses heart rate variability and inhibits neurotransmission to cardiac vagal neurons","volume":"89","author":"Griffioen","year":"2011","journal-title":"Cardiovasc Res."},{"key":"B89","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1172\/JCI15595","article-title":"Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons","volume":"110","author":"Yamamoto","year":"2002","journal-title":"J Clin Invest."},{"key":"B90","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1007\/s00125-015-3638-0","article-title":"Effects of exogenous glucagon-like peptide-1 on blood pressure, heart rate, gastric emptying, mesenteric blood flow and glycaemic responses to oral glucose in older individuals with normal glucose tolerance or type 2 diabetes","volume":"58","author":"Trahair","year":"2015","journal-title":"Diabetologia."},{"key":"B91","doi-asserted-by":"publisher","first-page":"e001075","DOI":"10.1161\/JAHA.114.001075","article-title":"Dipeptidyl-peptidase 4 inhibition and the vascular effects of glucagon-like peptide-1 and brain natriuretic peptide in the human forearm","volume":"3","author":"Devin","year":"2014","journal-title":"J Am Heart Assoc."},{"key":"B92","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1097\/MNH.0b013e3283414d40","article-title":"New insights into angiotensin receptor actions: from blood pressure to aging","volume":"20","author":"Stegbauer","year":"2011","journal-title":"Curr Opin Nephrol Hypertens."},{"key":"B93","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.yjmcc.2016.06.066","article-title":"A dipeptidyl peptidase-4 inhibitor ameliorates hypertensive cardiac remodeling via angiotensin-II\/sodium-proton pump exchanger-1 axis","volume":"98","author":"Kawase","year":"2016","journal-title":"J Mol Cell Cardiol."},{"key":"B94","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s10557-015-6592-7","article-title":"Preservation of glucagon-like peptide-1 level attenuates angiotensin II-induced tissue fibrosis by altering AT1\/AT 2 receptor expression and angiotensin-converting enzyme 2 activity in rat heart","volume":"29","author":"Zhang","year":"2015","journal-title":"Cardiovasc Drugs Ther."},{"key":"B95","doi-asserted-by":"publisher","first-page":"H1448","DOI":"10.1152\/ajpheart.01062.2003","article-title":"Coupling of angiotensin II AT1 receptors to neuronal NHE activity and carrier-mediated norepinephrine release in myocardial ischemia","volume":"286","author":"Reid","year":"2004","journal-title":"Am J Physiol Heart Circ Physiol."},{"key":"B96","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.ejphar.2013.08.043","article-title":"The regulation of NHE(1) and NHE(3) activity by angiotensin II is mediated by the activation of the angiotensin II type I receptor\/phospholipase C\/calcium\/calmodulin pathway in distal nephron cells","volume":"721","author":"Costa-Pessoa","year":"2013","journal-title":"Eur J Pharmacol."},{"key":"B97","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1097\/01.mnh.0000437542.77175.a0","article-title":"Physiology and pathophysiology of incretins in the kidney","volume":"23","author":"von Websky","year":"2014","journal-title":"Curr Opin Nephrol Hypertens."},{"key":"B98","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1097\/FJC.0000000000000258","article-title":"Diuretic and natriuretic effects of dipeptidyl peptidase-4 inhibitor teneligliptin: the contribution of glucagon-like peptide-1","volume":"66","author":"Moroi","year":"2015","journal-title":"J Cardiovasc Pharmacol."},{"key":"B99","doi-asserted-by":"publisher","first-page":"F414","DOI":"10.1152\/ajprenal.00174.2007","article-title":"Dipeptidyl peptidase IV inhibition downregulates Na+ - H+ exchanger NHE3 in rat renal proximal tubule","volume":"294","author":"Girardi","year":"2008","journal-title":"Am J Physiol Renal Physiol"},{"key":"B100","doi-asserted-by":"publisher","first-page":"F963","DOI":"10.1152\/ajprenal.00259.2012","article-title":"Natriuretic effect by exendin-4, but not the DPP-4 inhibitor alogliptin, is mediated via the GLP-1 receptor and preserved in obese type 2 diabetic mice","volume":"303","author":"Rieg","year":"2012","journal-title":"Am J Physiol Renal Physiol."},{"key":"B101","doi-asserted-by":"publisher","first-page":"F355","DOI":"10.1152\/ajprenal.00729.2010","article-title":"Mechanisms mediating the diuretic and natriuretic actions of the incretin hormone glucagon-like peptide-1","volume":"301","author":"Crajoinas","year":"2011","journal-title":"Am J Physiol Renal Physiol."},{"key":"B102","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.regpep.2006.12.016","article-title":"Glucagon-like peptide 1 receptor expression in primary porcine proximal tubular cells","volume":"141","author":"Schlatter","year":"2007","journal-title":"Regul Pept."},{"key":"B103","doi-asserted-by":"publisher","first-page":"C1238","DOI":"10.1152\/ajpcell.00186.2004","article-title":"Role of dipeptidyl peptidase IV in regulating activity of Na+\/H+ exchanger isoform NHE3 in proximal tubule cells","volume":"287","author":"Girardi","year":"2004","journal-title":"Am J Physiol Cell Physiol."},{"key":"B104","doi-asserted-by":"publisher","first-page":"e13503","DOI":"10.14814\/phy2.13503","article-title":"Glucagon-like peptide-1 acutely affects renal blood flow and urinary flow rate in spontaneously hypertensive rats despite significantly reduced renal expression of GLP-1 receptors","volume":"5","author":"Ronn","year":"2017","journal-title":"Physiol Rep."},{"key":"B105","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1038\/ajh.2008.174","article-title":"Natriuretic peptides: an update on bioactivity, potential therapeutic use, and implication in cardiovascular diseases","volume":"21","author":"Rubattu","year":"2008","journal-title":"Am J Hypertens."},{"key":"B106","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1373\/clinchem.2005.057638","article-title":"Dipeptidyl-peptidase IV converts intact B-type natriuretic peptide into its des-SerPro form","volume":"52","author":"Brandt","year":"2006","journal-title":"Clin Chem."},{"key":"B107","doi-asserted-by":"publisher","first-page":"R897","DOI":"10.1152\/ajpregu.00569.2006","article-title":"Des-serine-proline brain natriuretic peptide 3-32 in cardiorenal regulation","volume":"292","author":"Boerrigter","year":"2007","journal-title":"Am J Physiol Regul Integr Comp Physiol."},{"key":"B108","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1038\/nm.3128","article-title":"GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure","volume":"19","author":"Kim","year":"2013","journal-title":"Nat Med."},{"key":"B109","doi-asserted-by":"publisher","first-page":"20140892","DOI":"10.1098\/rsif.2014.0892","article-title":"Raison d'etre of insulin resistance: the adjustable threshold hypothesis","volume":"11","author":"Wang","year":"2014","journal-title":"J R Soc Interface."},{"key":"B110","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/1743-7075-11-25","article-title":"Association between prehypertension, metabolic and inflammatory markers, decreased adiponectin and enhanced insulinemia in obese subjects","volume":"11","author":"de Almeida","year":"2014","journal-title":"Nutr Metab"},{"key":"B111","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1172\/JCI118871","article-title":"Insulin-stimulated production of nitric oxide is inhibited by wortmannin","volume":"98","author":"Zeng","year":"1996","journal-title":"J Clin Invest."},{"key":"B112","doi-asserted-by":"publisher","first-page":"E1124","DOI":"10.1152\/ajpendo.00565.2005","article-title":"Insulin and IGF-I action on insulin receptors, IGF-I receptors, and hybrid insulin\/IGF-I receptors in vascular smooth muscle cells","volume":"291","author":"Johansson","year":"2006","journal-title":"Am J Physiol Endocrinol Metab."},{"key":"B113","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1161\/01.ATV.0000110444.59568.56","article-title":"Glargine and regular human insulin similarly acutely enhance endothelium-dependent vasodilatation in normal subjects","volume":"24","author":"Westerbacka","year":"2004","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"B114","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/0895-7061(95)96214-5","article-title":"Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives","volume":"8","author":"Ogihara","year":"1995","journal-title":"Am J Hypertens"},{"key":"B115","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1016\/j.molmet.2017.07.016","article-title":"Elevated hepatic DPP4 activity promotes insulin resistance and non-alcoholic fatty liver disease","volume":"6","author":"Baumeier","year":"2017","journal-title":"Mol Metab."},{"key":"B116","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.2337\/dc09-2062","article-title":"Weight loss, glycemic control, and changes in cardiovascular biomarkers in patients with type 2 diabetes receiving incretin therapies or insulin in a large cohort database","volume":"33","author":"Horton","year":"2010","journal-title":"Diabetes Care."},{"key":"B117","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1172\/JCI117433","article-title":"Insulin-mediated skeletal muscle vasodilation is nitric oxide dependent","volume":"94","author":"Steinberg","year":"1994","journal-title":"J Clin Invest."},{"key":"B118","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1097\/00006676-199508000-00014","article-title":"The effects of glucagon-like peptide-I (GLP-I) on hormone secretion from isolated human pancreatic islets","volume":"11","author":"Fehmann","year":"1995","journal-title":"Pancreas."},{"key":"B119","doi-asserted-by":"publisher","first-page":"e38744","DOI":"10.1371\/journal.pone.0038744","article-title":"Linagliptin improves insulin sensitivity and hepatic steatosis in diet-induced obesity","volume":"7","author":"Kern","year":"2012","journal-title":"PLoS ONE."},{"key":"B120","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1007\/s12272-016-0864-z","article-title":"Prevention and treatment effect of evogliptin on hepatic steatosis in high-fat-fed animal models","volume":"40","author":"Kim","year":"2017","journal-title":"Arch Pharm Res."},{"key":"B121","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.diabres.2016.12.011","article-title":"The effects of GLP-1 based therapies on postprandial haemodynamics: two randomised, placebo-controlled trials in overweight type 2 diabetes patients","volume":"124","author":"Smits","year":"2017","journal-title":"Diabetes Res Clin Pract."},{"key":"B122","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.bbrc.2016.02.019","article-title":"Reduced DPP4 activity improves insulin signaling in primary human adipocytes","volume":"471","author":"Rohrborn","year":"2016","journal-title":"Biochem Biophys Res Commun."},{"key":"B123","doi-asserted-by":"publisher","first-page":"81","DOI":"10.4149\/gpb2014032","article-title":"The effect of chronic peripheral nesfatin-1 application on blood pressure in normal and chronic restraint stressed rats: related with circulating level of blood pressure regulators","volume":"34","author":"Ayada","year":"2015","journal-title":"Gen Physiol Biophys."},{"key":"B124","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.2337\/diabetes.54.5.1340","article-title":"A role for iNOS in fasting hyperglycemia and impaired insulin signaling in the liver of obese diabetic mice","volume":"54","author":"Fujimoto","year":"2005","journal-title":"Diabetes."},{"key":"B125","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1161\/ATVBAHA.108.162073","article-title":"Dimethylarginine dimethylaminohydrolase overexpression enhances insulin sensitivity","volume":"28","author":"Sydow","year":"2008","journal-title":"Arterioscler Thromb Vasc Biol."}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2019.01050\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,13]],"date-time":"2019-05-13T09:28:59Z","timestamp":1557739739000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2019.01050\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,9]]},"references-count":125,"alternative-id":["10.3389\/fimmu.2019.01050"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2019.01050","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,9]]},"article-number":"1050"}}